Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

    Limited submission

    Accelerating Research and Development of Next Generation Vaccines against Malaria supports researchers developing highly effective, long-lasting vaccines to protect against malaria and inform other vaccine work.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: National Institutes of Health

    Due Dates: February 11, 2027 (Application deadline)

    Funding Amounts: $4,000,000 estimated total program funding; no cost sharing or matching required

    Summary: Supports research and preclinical development of highly effective, long-lasting malaria vaccines that may inform protection against other mosquito-borne diseases.

    Key Information: Clinical trials are not allowed, and applications involving foreign subawards or subcontracts will not be considered for funding.


    Description

    The National Institutes of Health supports research and/or preclinical development of highly efficacious malaria vaccines through this R61/R33 opportunity. The program seeks to capitalize on recent technological innovations, particularly structure-based immunogen design, improved formulations, and combination vaccines.

    Its goal is long-lasting, highly effective protection against malaria, one of the deadliest mosquito-borne diseases. Supported work should advance protection that can save lives and strengthen public health security in the United States. The program also seeks advances that can serve as a model for vaccine development against other mosquito-borne diseases or potentially provide protection against them.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.